NASDAQ : OCUL
Ocular Therapeutix, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.97 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.53B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.48B |
| Enterprise Value | 963.15M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 219.62M |
| Shares Outstanding | 219.62M |
| Shares Change (YoY) | +26.40% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 1.23% |
| Owned by Institutions (%) | 80.59% |
| Float | 184.69M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.41 |
| Forward PS | 26.84 |
| PB Ratio | 2.94 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 19.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.11 |
| Quick Ratio | 12.79 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.53 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -72.99% |
| Return on Assets (ROA) | -34.95% |
| Return on Invested Capital (ROIC) | -39.95% |
| Return on Capital Employed (ROCE) | -50.46% |
| Weighted Average Cost of Capital (WACC) | 11.00% |
| Revenue Per Employee | $160,169 |
| Profits Per Employee | -$927,529 |
| Employee Count | 325 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 67.07 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.22 |
| 52-Week Price Change | -42.11% |
| 50-Day Moving Average | 8.73 |
| 200-Day Moving Average | 9.10 |
| Relative Strength Index (RSI) | 39.77 |
| Average Volume (20 Days) | 2,876,560 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 28.76M |
| Short Previous Month | 29.41M |
| Short % of Shares Out | 13.10% |
| Short % of Float | 15.57% |
| Short Ratio (days to cover) | 7.60 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 52.06M |
| Gross Profit | -178.16M |
| Operating Income | -313.91M |
| Pretax Income | -301.45M |
| Net Income | -301.45M |
| EBITDA | -308.46M |
| EBIT | -313.91M |
| Loss Per Share | -$1.41 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 598.64M |
| Total Debt | 79.38M |
| Net Cash | 519.26M |
| Net Cash Per Share | $2.36 |
| Equity (Book Value) | 520.04M |
| Book Value Per Share | 2.37 |
| Working Capital | 595.25M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -238.24M |
| Capital Expenditures | -16.86M |
| Depreciation & Amortization | 5.45M |
| Net Borrowing | n/a |
| Free Cash Flow | -255.10M |
| FCF Per Share | -$1.16 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -603.03% |
| Pretax Margin | -579.09% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.40% |
| Shareholder Yield | -26.40% |
| Earnings Yield | -20.95% |
| FCF Yield | -16.67% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $25.45 |
| Price Target Difference | 277.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 74.78% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.42 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |